www.fdanews.com/articles/149411-prescriptions-for-merck-rsquo-s-singulair-plunge-after-loss-of-u-s-patent
Prescriptions for Merck’s Singulair Plunge After Loss of U.S. Patent
September 12, 2012
Weekly prescriptions for Merck’s asthma and allergy treatment Singulair (montelukast) plunged nearly 90 percent within four weeks of the August introduction of competing generic copies.
NASDAQ
NASDAQ